mouse cd47  (R&D Systems)

Journal: Cell Death & Disease

Article Title: Targeting hypoxic exosomal IGFBP2 overcomes CD47-mediated immune evasion in glioblastoma

doi: 10.1038/s41419-026-08430-9

Figure Lengend Snippet: A , B Flow cytometry analysis and quantification of macrophages phagocytosis in GSC20 and GSC267 cells treated with IgG or blocking antibody anti-CD47 and anti-IGFBP2. Right graph: Quantification of the percentage of macrophages phagocytosis. ( n = 3) C Schematic representation of the homologous models established to evaluate the response to anti-CD47 and anti-IGFBP2 therapy. D Bioluminescence imaging of xenograft models established with GSC267 cells treated with anti-CD47 and anti-IGFBP2 antibody on the indicated days after surgery. E In vivo tumor activities were assessed by bioluminescent in vivo imaging system on the indicated days after surgery. ( n = 5) F Kaplan-Meier survival curves for animals in different groups, n = 5 for each group. G A proposed model of hypoxia-exosomal IGFBP2-CD47 axis in the regulation of GBM immune evasion. Data are presented as the mean ± SD. Statistical significance was determined using one-way ANOVA and the log-rank test (* P < 0.05; ** P < 0.01; *** P < 0.001).

Article Snippet: Treatments included tail vein injections of anti-CD47 reagent (BE0019, BioXcell), anti-IGFBP2 antibody (#AF674, R&D Systems), or isotype control antibody (#BP0089, BioXcell) three times a week after tumor implantation.

Techniques: Flow Cytometry, Blocking Assay, Imaging, In Vivo, In Vivo Imaging